SCHEMBL4810690

SCHEMBL4810690

CN(C)C(=O)C=Cc1cnc(-c2ccccc2)o1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.52
IP6K1 Q92551 1/20 0.44
IP6K2 Q9UHH9 1/20 0.44
KDM4E B2RXH2 6/20 0.41
HPGD P15428 5/20 0.41
NPC1 O15118 5/20 0.41
ALDH1A1 P00352 5/20 0.41
RAB9A P51151 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
TP53 P04637 3/20 0.41
HSD17B10 Q99714 3/20 0.41
GAA P10253 3/20 0.41
LMNA P02545 3/20 0.41
CYP1A2 P05177 1/20 0.41
GLA P06280 1/20 0.41
CYP2C9 P11712 1/20 0.41
NFKB1 P19838 1/20 0.41
CYP2C19 P33261 1/20 0.41
CASP3 P42574 1/20 0.41
NFKB2 Q00653 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4810694 0.72 ALDH1A1 (0.56) KDM4EHPGDNPC1ALDH1A1RAB9A
SCHEMBL14196049 0.72 ALDH1A1 (0.56) KDM4EHPGDNPC1ALDH1A1RAB9A
SCHEMBL7450038 0.72 ALOX15 (0.53) KDM4EHPGDNPC1ALDH1A1RAB9A
SCHEMBL4808364 0.69 PIN1 (0.48) NR4A2IP6K1IP6K2NPC1RAB9A
SCHEMBL9259362 0.69 ALOX15 (0.55) KDM4EHPGDNPC1ALDH1A1RAB9A
SCHEMBL9590158 0.69 HDAC2 (0.59) NR4A2IP6K1IP6K2NPC1GLA
SCHEMBL21219959 0.69 TSHR (0.53) KDM4EHPGDNPC1ALDH1A1RAB9A
SCHEMBL9259662 0.68 SMN1; SMN2 (0.53) KDM4EHPGDNPC1ALDH1A1RAB9A
SCHEMBL9259659 0.68 SMN1; SMN2 (0.53) KDM4EHPGDNPC1ALDH1A1RAB9A
N,N-Dimethylcinnamamide SCHEMBL3743395 0.68 NPC1 (0.65) IP6K1IP6K2NPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7361665-B2 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-04-22 US disclosed
US-20040097531-A1 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097531-A1 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases LCK, AURKC, CDK5 NR4A2 3964/4885IP6K1 309/4885IP6K2 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.